DE69710182T2 - Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung - Google Patents

Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung

Info

Publication number
DE69710182T2
DE69710182T2 DE69710182T DE69710182T DE69710182T2 DE 69710182 T2 DE69710182 T2 DE 69710182T2 DE 69710182 T DE69710182 T DE 69710182T DE 69710182 T DE69710182 T DE 69710182T DE 69710182 T2 DE69710182 T2 DE 69710182T2
Authority
DE
Germany
Prior art keywords
pct
derivatives
tetrahydrobetacarbolin
preventing metastasis
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69710182T
Other languages
English (en)
Other versions
DE69710182D1 (de
Inventor
Silvano Spinelli
Ernesto Menta
Hans-Willi Krell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT96MI000664 external-priority patent/IT1283574B1/it
Priority claimed from IT96MI002241 external-priority patent/IT1286060B1/it
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE69710182D1 publication Critical patent/DE69710182D1/de
Publication of DE69710182T2 publication Critical patent/DE69710182T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
DE69710182T 1996-04-04 1997-03-27 Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung Expired - Fee Related DE69710182T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96MI000664 IT1283574B1 (it) 1996-04-04 1996-04-04 Uso di derivati beta-carbolinici come agenti antimetastatici
IT96MI002241 IT1286060B1 (it) 1996-10-29 1996-10-29 Uso di derivati tetraidro-beta-carbolinici come agenti antimetastatici
PCT/EP1997/001582 WO1997037658A1 (en) 1996-04-04 1997-03-27 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents

Publications (2)

Publication Number Publication Date
DE69710182D1 DE69710182D1 (de) 2002-03-14
DE69710182T2 true DE69710182T2 (de) 2002-08-29

Family

ID=26331376

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710182T Expired - Fee Related DE69710182T2 (de) 1996-04-04 1997-03-27 Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung

Country Status (15)

Country Link
US (1) US6069150A (de)
EP (1) EP0891187B1 (de)
JP (1) JP2000508302A (de)
KR (1) KR20000005175A (de)
CN (1) CN1113648C (de)
AT (1) ATE212549T1 (de)
AU (1) AU710079B2 (de)
BR (1) BR9708480A (de)
CA (1) CA2250898A1 (de)
DE (1) DE69710182T2 (de)
DK (1) DK0891187T3 (de)
ES (1) ES2169857T3 (de)
PT (1) PT891187E (de)
TR (1) TR199801970T2 (de)
WO (1) WO1997037658A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040253891A1 (en) * 2000-09-12 2004-12-16 Schierenbeck Alan W. Composite structure for protective garment
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
DE60216745T2 (de) * 2001-04-25 2007-05-16 Lilly Icos Llc, Wilmington Chemische Verbindungen
JP2005508968A (ja) * 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体
CN100503607C (zh) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
JP2007518822A (ja) * 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
SG151267A1 (en) * 2004-03-15 2009-04-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
CN100360129C (zh) * 2004-09-03 2008-01-09 首都医科大学 去氢胡秃子碱衍生物、其合成方法及其应用
WO2006070385A1 (en) * 2004-12-27 2006-07-06 Council Of Scientific And Industrial Research 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
ITMI20071163A1 (it) * 2007-06-08 2008-12-09 C4T S C A R L Arilsolfonammidi dela beta-carbolina metodo per prepararle e composizione che le comprende
CN102083830B (zh) 2008-03-24 2014-11-12 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
PL2434891T3 (pl) 2009-05-27 2020-12-28 Ptc Therapeutics, Inc. Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych
JP2012528181A (ja) 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド 置換テトラヒドロβ−カルボリンの製造方法
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
CN101906102B (zh) * 2009-06-02 2012-08-29 首都医科大学 β-咔啉类生物碱衍生物及其制备方法和应用
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
CN104744460B (zh) * 2013-12-30 2017-06-16 南开大学 β‑咔啉，二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CA2972065A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
CA3022088A1 (en) * 2016-03-29 2017-10-05 Georgia State University Research Foundation, Inc. Calcium sensing receptors, ligands, compositions, and methods of use
AU2018255294B2 (en) * 2017-04-17 2022-07-28 Ampersand Biopharmaceuticals, Llc Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
EP3664803A4 (de) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. Dhodh-inhibitor zur verwendung bei der behandlung von blutkrebs
EP3681479B1 (de) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Natriumhydrogencarbonat zur verwendung in der behandlung von gicht und verwandten erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3395M (fr) * 1963-07-30 1965-06-28 Roussel Uclaf Nouveau médicament notamment pour le traitement des états neurodépressifs et des psychoses d'anxiété.
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4539407A (en) * 1983-12-13 1985-09-03 American Home Products Corporation β-Carboline anticonvulsants
US5162336A (en) * 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5244905A (en) * 1990-08-31 1993-09-14 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives
WO1994021612A1 (en) * 1993-03-18 1994-09-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
JP2000508302A (ja) 2000-07-04
AU2506997A (en) 1997-10-29
ES2169857T3 (es) 2002-07-16
AU710079B2 (en) 1999-09-16
BR9708480A (pt) 1999-04-13
DK0891187T3 (da) 2002-04-29
TR199801970T2 (xx) 2000-10-23
US6069150A (en) 2000-05-30
CN1113648C (zh) 2003-07-09
CN1215333A (zh) 1999-04-28
WO1997037658A1 (en) 1997-10-16
ATE212549T1 (de) 2002-02-15
EP0891187A1 (de) 1999-01-20
CA2250898A1 (en) 1997-10-16
DE69710182D1 (de) 2002-03-14
PT891187E (pt) 2002-06-28
EP0891187B1 (de) 2002-01-30
KR20000005175A (ko) 2000-01-25

Similar Documents

Publication Publication Date Title
DE69710182D1 (de) Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung
ATE219064T1 (de) Piperazinderivative als tachykinin antagonisten
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
SE9604793D0 (sv) New polymorphs
DE69705300T2 (de) Cyclopropylalkansäurederivate
ES2193154T3 (es) Procedimiento para la preparacion de 9-desoxotaxanos.
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
PT918744E (pt) Separacao racemica da cetamina
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DK0865498T3 (da) Fremgangsmåde til fremstilling af substituerede arylmælkesyreholdige cyclodepsipeptider med 24 ringatomer
DE59712632D1 (de) Verfahren zur herstellung von 3-pyrrolin-2-carbonsäure-derivaten
US5563157B1 (en) Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
DK0883628T3 (da) 17beta- (2-oxo-tetrahydrofuran-4-yl) -thioandrostanderivater (17beta- (gamma-smørsyrelacton) -thioderivater) til behandling
ES2154457T3 (es) Derivados de ciclohexadieno sustituidos con dimetilo.
ATE209493T1 (de) Verwendung von aspirochlorine oder dessen derivaten zur immunsuppression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee